Proximity-Based Therapeutics: Targeted Protein Degradation and Other Pharmacological Approaches (B2)
February 16-19, 2025
| Eldorado Hotel & Spa, Santa Fe, NM, United States
Philip Chamberlain and Fleur M. Ferguson
Scholarship Deadline: Nov. 21, 2024 | Abstract Deadline: Jan. 24, 2025 | Early Registration Deadline: Dec. 20, 2024
Sunday, February 16, 2025
| 4:00–8:00 PM |
Registration |
Concourse |
| 6:00–8:00 PM |
Welcome Mixer |
Cava Santa Fe |
Monday, February 17, 2025
| 7:00–8:00 AM |
Breakfast |
Anasazi Ballroom |
| 7:30–8:00 AM |
Poster Setup |
Anasazi Ballroom |
| 7:45–7:00 PM |
Poster Viewing |
Anasazi Ballroom |
| 8:00–9:00 AM |
Welcome and Keynote Address |
Eldorado Ballroom |
| |
* Philip Chamberlain, Neomorph, Inc.
Session Chair |
|
| |
Benjamin F. Cravatt III, The Scripps Research Institute
Activity-Based Proteomics – Protein and Ligand Discovery on A Global Scale |
|
| 9:00–11:15 AM |
Molecular and Structural Biology of Induced Proximity Drugs |
Eldorado Ballroom |
| |
Brenda A Schulman, Max Planck Institute of Biochemistry
E3-Ligase Activation, Regulation and Structure |
|
| |
Georg Petzold, Monte Rosa Therapeutics
Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition |
|
| |
Hlib Razumkov, Stanford University
Short Talk: Discovery of CRBN-Dependent WEE1 Molecular Glue Degraders From A Multicomponent Combinatorial Library |
|
| |
Björn Schwalb, NEOsphere Biotechnologies GmbH
Short Talk: Unbiased Mapping of Cereblon Neosubstrate Landscape by High-Throughput Proteomics |
|
| |
* Jin Wang, Baylor College of Medicine
Short Talk: Expanding Cereblon Neosubstrates Beyond G-Loops |
|
| 9:30–9:50 AM |
Coffee Break |
Concourse |
| 11:15–12:30 PM |
Lunch |
Anasazi Ballroom |
| 12:00–2:30 PM |
Poster Session 1 |
Anasazi Ballroom |
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
Eldorado Ballroom |
| |
Stefan A Harry, Massachusetts General Hospital and Harvard University
Systematic Targeting of Protein Complexes with Molecular COUPLrs |
|
| |
* Charlene M Magtoto, Walter and Eliza Hall Institute of Medical Research
Developing a Pipeline to Validate Potential Therapeutic Targets In Vivo Using Tag Degraders |
|
| |
William Farnaby, University of Dundee
High-Throughput Multi-Step Degrader Synthesis and Screening Via an Orthogonally Reactive Linker Concept |
|
| |
HONG-YU Li, University of Texas Health San Antonio
A Mechanistic Insight into Cellular Permeability of bRo5 Molecules and Its Applications |
|
| |
Kyubin Hwang, Yonsei University College of Medicine
Discovery of a Potent METTL3 PROTAC With Antitumor Effects Against Acute Myeloid Leukemia and Gastric Cancer |
|
| |
Felipe de Sousa e Melo, Amgen
Single Cell Guided Design of Toxicity-Sparing Antibody Antagonists |
|
| |
Jesus A Izaguirre, Atommap Corporation
Harnessing Biomolecular Motion for Reprogramming of Protein Function: Introducing GlueMap for Molecular Glue Discovery |
|
| 4:30–5:00 PM |
Coffee Available |
Concourse |
| 5:00–7:00 PM |
New Induced Proximity Approaches |
Eldorado Ballroom |
| |
* Sai Gourisankar, Stanford
Session Chair |
|
| |
Gerald R. Crabtree, Stanford University
Rewiring Cancer Drivers to Activate Programmed Cell Death Pathways |
|
| |
Xin Zhou, Dana-Farber Cancer Institute
Novel Bifunctional Antibodies for Targeted Membrane Protein Degradation |
|
| |
Kevan M. Shokat, University of California, San Francisco
Proximity Approaches to Hijack Immune Signaling and Recognition |
|
| |
Daniel K Nomura, University of California, Berkeley
Covalent Ligands to Drive Proximity |
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Tuesday, February 18, 2025
| 7:00–8:00 AM |
Breakfast |
Anasazi Ballroom |
| 8:00–11:00 AM |
Innovation in Induced Proximity Drug Discovery |
Eldorado Ballroom |
| |
William Forrester, Novartis
The Novartis Targeted Protein Degradation Platform |
|
| |
* Fleur M. Ferguson, University of California, San Diego
Interrogating the Druggable Proteome with Proximity Pharmacology |
|
| |
Philip Chamberlain, Neomorph, Inc.
Expanding the Scope of Glue Degraders |
|
| |
Anil Vasudevan, AbbVie, Inc.
The Hunt for Ligands for Tissue-Restricted Ligases |
|
| |
Christine Jones, Arvinas, Inc.
Short Talk: Development Of Potent, Orally Bioavailable PROTAC LRRK2 Degrader Molecules As Potential Disease Modifying Therapeutics For Neurodegenerative Disorders |
|
| |
Lindsey Lin, UCSF
Short Talk: MultiMap: Multiscale Interaction Profiling for Cell Surface Neighborhoods |
|
| 9:00–9:20 AM |
Coffee Break |
Concourse |
| 9:20–9:25 AM |
Award Recipient Acknowledgement |
Eldorado Ballroom |
| 11:00–1:00 PM |
Poster Setup |
Anasazi Ballroom |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Anasazi Ballroom |
| 1:30–3:00 PM |
Women in TPD&IP Networking Social (Sponsored by Neomorph) - OPEN TO ALL!! |
Anasazi Ballroom |
| |
* Fleur M. Ferguson, University of California, San Diego
Session Lead |
|
| |
* Danette L Daniels, Foghorn Therapeutics, Inc
Session lead |
|
| 3:00–4:30 PM |
Career Roundtable |
Eldorado Ballroom |
| |
Francesca Ester Morreale, Francis Crick Institute
Group Leader |
|
| |
Felipe de Sousa e Melo, Amgen
Director - Research Technology and Emerging Modalities |
|
| |
Georg Petzold, Monte Rosa Therapeutics
Senior Scientist II, Discovery Technologies |
|
| |
Nicola J. Allen, The Salk Institute for Biological Studies
Associate Professor |
|
| 4:30–5:00 PM |
Coffee Available |
Concourse |
| 5:00–7:00 PM |
Clinical Progress in Proximity Technologies |
Eldorado Ballroom |
| |
* Michelle R. Arkin, University of California, San Francisco
Session Chair |
|
| |
Danette L Daniels, Foghorn Therapeutics, Inc
Clinical Progress in Degrading Epigenetic Disease Drivers |
|
| |
Vivek K. Arora, Bristol Myers Squibb
Clinical Advances in Cereblon-based Heterobifunctional and Glue Degraders |
|
| |
Juliet Williams, Kymera Therapeutics
Preclinical to Clinical Translation: Building an Immunology Pipeline of Heterobifunctional Degraders |
|
| |
Lynda Groocock, Bristol Myers Squibb
Short Talk: BCL6 Ligand Directed Degrader (LDD) BMS-986458 is a First-In-Class, Highly Selective, Efficacious and Well Tolerated Potential Treatment for B-cell Non-Hodgkin’s Lymphoma |
|
| |
Lucilia Pereira Mouries, Health & Environmental Sciences Institute (HESI)
Short Talk: Collaborative Approaches to Advance Integrated Safety Assessment of Targeted Protein Degraders |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Anasazi Ballroom |
| 7:30–10:00 PM |
Poster Session 2 |
Anasazi Ballroom |
Wednesday, February 19, 2025
| 7:00–8:00 AM |
Breakfast |
Anasazi Ballroom |
| 8:00–11:00 AM |
Beyond Degredation: New Applications of Induced Proximity |
Eldorado Ballroom |
| |
* Lauren V Albrecht, University of California Irvine
Session Chair |
|
| |
Steven Banik, Stanford University
Targeted Protein Relocalization |
|
| |
Amit Choudhary, Harvard Medical School
A Scalable Design for Proximity-Inducing Molecules |
|
| |
Michelle R. Arkin, University of California, San Francisco
Hacking Native Protein-Protein Interaction Networks with Molecular Glues |
|
| |
Francesca Ester Morreale, Francis Crick Institute
Enabling Targeted Protein Degradation in Bacteria |
|
| |
Lawrence Hamann, Interdict Bio, Inc.
Short Talk: Sequence Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality |
|
| |
William J Gibson, Dana Farber Cancer Institute
Short Talk: p53 Protein Abundance is a Therapeutic Window Across TP53 Mutant Cancers and is Targetable With Proximity Inducing Small Molecules |
|
| 9:00–9:20 AM |
Coffee Break |
Concourse |
| 11:00–2:30 PM |
On Own for Lunch |
|
| 3:00–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
Eldorado Ballroom |
| |
Alexandra Lantermann, Photys Therapeutics
P53-Y220C-BET-Bifunctionals Drive p53-Y220C-Mutant Cancer Cells into Apoptosis |
|
| |
Markella Konstantinidou, University of California, San Francisco
Rational Approaches for The Systematic Identification of Covalent Molecular Glues |
|
| |
Jean-Francois Brazeau, Plexium
Ultra-High-Throughput Miniaturized Cell-Based Assays to Discover CDK2 Molecular Glue Degraders |
|
| |
Dhanusha Nalawansha, Amgen
LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation |
|
| |
Hadir Marei, Genentech, Roche
Target Clearance: Targeted Protein Degradation At The Cell Surface |
|
| |
* George M Burslem, University of Pennsylvania
Pooled Endogenous Protein Tagging and Recruitment for Scalable Discovery of Effectors for Induced Proximity Therapeutics |
|
| 4:30–5:00 PM |
Coffee Available |
Concourse |
| 5:00–6:45 PM |
Hijacking New Components of the Degradation Machinery |
Eldorado Ballroom |
| |
* Danette L Daniels, Foghorn Therapeutics, Inc
Session Chair |
|
| |
Stefan Knapp, SGC Frankfurt
E3-Ligases and updates from the SGC |
|
| |
Natalie Scholes, CeMM
When Inhibitors Act as Degraders: Supercharging Protein Turnover via Endogenous Degradation Routes |
|
| |
Henry M. Colecraft, Columbia University
Hacking the Polyubiquitin Code to Understand and Manipulate Ion Channel Functional Expression |
|
| |
Laurence J Seabrook, University of California, Irvine
Short Talk: Methylarginine Targeting Chimeras for Lysosomal Degradation of Intracellular Proteins |
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
Eldorado Ballroom |
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Anasazi Ballroom |
| 8:00–9:00 PM |
Entertainment |
Eldorado Ballroom |
| 8:00–9:00 PM |
Cash Bar |
Anasazi Ballroom |
Thursday, February 20, 2025
